IGEA Pharma NV
SIX:IGPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IGEA Pharma NV
SIX:IGPH
|
NL |
|
M
|
Million Hope Industries Holdings Ltd
HKEX:1897
|
HK |
|
Worldline SA
PAR:WLN
|
FR |
|
Doma Holdings Inc
NYSE:DOMA
|
US |
|
Warpaint London PLC
LSE:W7L
|
UK |
|
Provident Investasi Bersama Tbk PT
IDX:PALM
|
ID |
|
E
|
EarthRenew Inc
CNSX:ERTH
|
CA |
|
Todd River Resources Ltd
ASX:TRT
|
AU |
|
Regenerative Medical Technology Group Inc
OTC:RMTG
|
US |
|
U
|
Updater Services Ltd
NSE:UDS
|
IN |
|
W
|
Wonik IPS Co Ltd
KOSDAQ:240810
|
KR |
|
Timken Co
NYSE:TKR
|
US |
|
G
|
Guangdong Marubi Biotechnology Co Ltd
SSE:603983
|
CN |
|
U
|
UOL Group Ltd
OTC:UOLGF
|
SG |
|
E
|
Everest Medicines Ltd
HKEX:1952
|
CN |
|
LVMH Moet Hennessy Louis Vuitton SE
XETRA:MOH
|
FR |
|
M
|
Macrogen Inc
KOSDAQ:038290
|
KR |
IGEA Pharma NV
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
